

Phase I Study of the Intravenous Administration of *Atte*
typhimurium to Patients With Metastatic Melanoma

Journal of Clinical Oncology

20, 142-152

DOI: 10.1200/jco.2002.20.1.142

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bugs as drugs for cancer. <i>Immunology</i> , 2002, 107, 10-19.	2.0	19
2	Pilot trial of genetically modified, attenuated <i>Salmonella</i> expressing the <i>E. coli</i> cytosine deaminase gene in refractory cancer patients. <i>Cancer Gene Therapy</i> , 2003, 10, 737-744.	2.2	277
3	Clostridia in cancer therapy. <i>Nature Reviews Microbiology</i> , 2003, 1, 237-242.	13.6	137
4	Bacteria as tumour-targeting vectors. <i>Lancet Oncology</i> , The, 2003, 4, 548-556.	5.1	257
5	Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant <i>Salmonella</i> in tumours. <i>British Journal of Cancer</i> , 2003, 89, 1796-1801.	2.9	36
6	<i>Salmonella enterica</i> Serovar Typhimurium Expressing Mutant Lipid A with Decreased Endotoxicity Causes Maturation of Murine Dendritic Cells. <i>Infection and Immunity</i> , 2003, 71, 6132-6140.	1.0	16
7	Continuous Intravenous Administration of Live Genetically Modified <i>Salmonella</i> Typhimurium in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2003, 26, 179-180.	1.2	134
9	Exploiting tumour hypoxia in cancer treatment. <i>Nature Reviews Cancer</i> , 2004, 4, 437-447.	12.8	2,406
10	Potential therapeutic applications of recombinant, invasive <i>E. coli</i> . <i>Gene Therapy</i> , 2004, 11, 1224-1233.	2.3	69
11	Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 751-758.	1.3	22
12	Positron emission tomography (PET) imaging of tumor-localized <i>Salmonella</i> expressing HSV1-TK. <i>Cancer Gene Therapy</i> , 2005, 12, 101-108.	2.2	78
13	Pharmacologic and Toxicologic Evaluation of <i>C. novyi</i> -NT Spores. <i>Toxicological Sciences</i> , 2005, 88, 562-575.	1.4	90
14	Systemic Administration of an Attenuated, Tumor-Targeting <i>Salmonella</i> typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation. <i>Clinical Cancer Research</i> , 2005, 11, 4827-4834.	3.2	147
15	Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing <i>Salmonella</i> typhimurium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 755-760.	3.3	439
16	Cancer Immunotherapy Based on Killing of <i>Salmonella</i> -Infected Tumor Cells. <i>Cancer Research</i> , 2005, 65, 3920-3927.	0.4	157
17	Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. <i>Nature Biotechnology</i> , 2006, 24, 697-702.	9.4	239
18	Bacterial gene therapy strategies. <i>Journal of Pathology</i> , 2006, 208, 290-298.	2.1	121
19	Bacteria in gene therapy: bactofection versus alternative gene therapy. <i>Gene Therapy</i> , 2006, 13, 101-105.	2.3	94

#	ARTICLE	IF	CITATIONS
20	Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. <i>Biotechnology and Bioengineering</i> , 2006, 94, 710-721.	1.7	173
21	Use of bacteria in anti-cancer therapies. <i>BioEssays</i> , 2006, 28, 84-94.	1.2	72
22	Therapeutic biology: Checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. <i>Journal of Cellular Physiology</i> , 2006, 209, 695-700.	2.0	7
23	Targeted Therapy with a Salmonella Typhimurium Leucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude Mice. <i>Cancer Research</i> , 2006, 66, 7647-7652.	0.4	278
24	Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10170-10174.	3.3	229
25	Attenuated <i>Salmonella</i> engineered to produce human cytokine LIGHT inhibit tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12879-12883.	3.3	153
26	Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. <i>Vaccine</i> , 2007, 25, 4183-4192.	1.7	69
27	Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. <i>International Journal of Cancer</i> , 2007, 121, 666-674.	2.3	56
28	Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. <i>Journal of Gene Medicine</i> , 2007, 9, 416-423.	1.4	63
29	In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit. <i>Nature Methods</i> , 2007, 4, 937-942.	9.0	84
30	Attenuated Salmonella typhimurium with IL-2 Gene Reduces Pulmonary Metastases in Murine Osteosarcoma. <i>Clinical Orthopaedics and Related Research</i> , 2008, 466, 1285-1291.	0.7	49
31	Intra-tumoral <i>Salmonella typhimurium</i> induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. <i>European Journal of Immunology</i> , 2008, 38, 1937-1947.	1.6	43
32	Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. <i>Biotechnology and Bioengineering</i> , 2008, 100, 567-578.	1.7	46
33	Bacterial therapies: completing the cancer treatment toolbox. <i>Current Opinion in Biotechnology</i> , 2008, 19, 511-517.	3.3	70
34	Attenuated Bacteria as Effectors in Cancer Immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2008, 1138, 351-357.	1.8	32
35	IL-18-producing Salmonella inhibit tumor growth. <i>Cancer Gene Therapy</i> , 2008, 15, 787-794.	2.2	105
36	Suicide gene/prodrug therapy using salmonella-mediated delivery of <i>Escherichia coli</i> purine nucleoside phosphorylase gene and 6-methoxypurine 2 ^{deoxy} deoxyriboside in murine mammary carcinoma 4T1 model. <i>Cancer Science</i> , 2008, 99, 1172-1179.	1.7	27
37	Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1113-1116.	3.0	92

#	ARTICLE	IF	CITATIONS
38	<i>Escherichia coli</i> Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging. <i>Clinical Cancer Research</i> , 2008, 14, 2295-2302.	3.2	82
39	Armed & dangerous. <i>Science-Business EXchange</i> , 2008, 1, 718-718.	0.0	0
40	Attenuated <i>Salmonella</i> Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4259-4266.	3.2	78
41	<i>Salmonella</i> Promoters Preferentially Activated Inside Tumors. <i>Cancer Research</i> , 2008, 68, 4827-4832.	0.4	73
42	msbB deletion confers acute sensitivity to CO2 in <i>Salmonella enterica</i> serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf. <i>BMC Microbiology</i> , 2009, 9, 170.	1.3	12
43	Novel cancer vaccine based on genes of <i>Salmonella</i> pathogenicity island 2. <i>International Journal of Cancer</i> , 2010, 126, 2622-2634.	2.3	80
44	Cancer metastasis directly eradicated by targeted therapy with a modified <i>Salmonella typhimurium</i>. <i>Journal of Cellular Biochemistry</i> , 2009, 106, 992-998.	1.2	125
45	Tumor-targeting amino acid auxotrophic <i>Salmonella typhimurium</i> . <i>Amino Acids</i> , 2009, 37, 509-521.	1.2	32
46	Recombinant <i>E. coli</i> LLO/OVA vaccination effectively inhibits murine melanoma metastasis to lung by CD8+T cells immunity. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2009, 21, 44-49.	0.7	2
47	<i>Salmonella typhimurium</i> engineered to produce CCL21 inhibit tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 769-775.	2.0	101
48	Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. <i>Gene Therapy</i> , 2009, 16, 329-339.	2.3	154
49	Tumour-targeted delivery of TRAIL using <i>Salmonella typhimurium</i> enhances breast cancer survival in mice. <i>British Journal of Cancer</i> , 2009, 101, 1683-1691.	2.9	152
50	Biological Gene Delivery Vehicles: Beyond Viral Vectors. <i>Molecular Therapy</i> , 2009, 17, 767-777.	3.7	282
51	Humoral Immune Responses Inhibit the Antitumor Activities Mediated by <i>Salmonella enterica</i> Serovar choleraesuis. <i>Journal of Immunotherapy</i> , 2009, 32, 376-388.	1.2	24
52	<i>Salmonella</i> "allies in the fight against cancer. <i>Journal of Molecular Medicine</i> , 2010, 88, 763-773.	1.7	83
53	Molecular Imaging of Biological Gene Delivery Vehicles for Targeted Cancer Therapy: Beyond Viral Vectors. <i>Nuclear Medicine and Molecular Imaging</i> , 2010, 44, 15-24.	0.6	17
54	Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. <i>Cancer Science</i> , 2010, 101, 1925-1932.	1.7	62
55	Targeted therapy of spinal cord glioma with a genetically modified <i>Salmonella typhimurium</i>. <i>Cell Proliferation</i> , 2010, 43, 41-48.	2.4	100

#	ARTICLE	IF	CITATIONS
56	An enteric pathogen <i>Salmonella enterica</i> serovar Typhimurium suppresses tumor growth by downregulating CD44 ^{high} and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. <i>Cancer Gene Therapy</i> , 2010, 17, 97-108.	2.2	32
57	Engineering the perfect (bacterial) cancer therapy. <i>Nature Reviews Cancer</i> , 2010, 10, 785-794.	12.8	648
59	Safety and immunogenicity of <i>Salmonella typhimurium</i> expressing C-terminal truncated human IL-2 in a murine model. <i>Biologics: Targets and Therapy</i> , 2010, 4, 61.	3.0	9
60	Virulence, Inflammatory Potential, and Adaptive Immunity Induced by <i>Shigella flexneri</i> msbB Mutants. <i>Infection and Immunity</i> , 2010, 78, 400-412.	1.0	40
61	High-Throughput Screening for <i>Salmonella</i> Avirulent Mutants That Retain Targeting of Solid Tumors. <i>Cancer Research</i> , 2010, 70, 2165-2170.	0.4	46
62	Vessel destruction by tumor-targeting <i>Salmonella typhimurium</i> A1-R is enhanced by high tumor vascularity. <i>Cell Cycle</i> , 2010, 9, 4518-4524.	1.3	99
63	Bacteria as tumor therapeutics?. <i>Bioengineered Bugs</i> , 2010, 1, 146-147.	2.0	41
64	Myristoylation negative msbB-mutants of probiotic <i>E. coli</i> Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. <i>Bioengineered Bugs</i> , 2010, 1, 139-145.	2.0	13
65	Bacteria as vectors for gene therapy of cancer. <i>Bioengineered Bugs</i> , 2010, 1, 385-394.	2.0	139
66	Monotherapy with a Tumor-Targeting Mutant of <i>S. typhimurium</i> Inhibits Liver Metastasis in a Mouse Model of Pancreatic Cancer. <i>Journal of Surgical Research</i> , 2010, 164, 248-255.	0.8	125
67	Tumor-targeted delivery of biologically active TRAIL protein. <i>Cancer Gene Therapy</i> , 2010, 17, 334-343.	2.2	31
68	Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. <i>Gene Therapy</i> , 2011, 18, 425-431.	2.3	50
70	In tumors <i>Salmonella</i> migrate away from vasculature toward the transition zone and induce apoptosis. <i>Cancer Gene Therapy</i> , 2011, 18, 457-466.	2.2	134
71	Bio-inspired, bioengineered and biomimetic drug delivery carriers. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 521-535.	21.5	1,038
72	Antibiotic control of tumor-colonizing <i>Salmonella enterica</i> serovar Typhimurium. <i>Experimental Biology and Medicine</i> , 2011, 236, 1282-1290.	1.1	9
73	Palmitoylation State Impacts Induction of Innate and Acquired Immunity by the <i>Salmonella enterica</i> Serovar Typhimurium msbB Mutant. <i>Infection and Immunity</i> , 2011, 79, 5027-5038.	1.0	42
74	Proteomic Screening of Anaerobically Regulated Promoters from <i>Salmonella</i> and Its Antitumor Applications. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M111.009399.	2.5	23
75	Oral Delivery of the Sj23LHD-GST Antigen by <i>Salmonella typhimurium</i> Type III Secretion System Protects against <i>Schistosoma japonicum</i> Infection in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1313.	1.3	23

#	ARTICLE	IF	CITATIONS
76	Bugging Tumors. <i>Cancer Discovery</i> , 2012, 2, 588-590.	7.7	19
77	<i>Escherichia coli</i> Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein. <i>Applied and Environmental Microbiology</i> , 2012, 78, 7603-7610.	1.4	96
78	A Bioluminescent Transposon Reporter-Trap Identifies Tumor-Specific Microenvironment-Induced Promoters in <i>Salmonella</i> for Conditional Bacterial-Based Tumor Therapy. <i>Cancer Discovery</i> , 2012, 2, 624-637.	7.7	58
79	Inhibition and eradication of human glioma with tumor-targeting <i>Salmonella typhimurium</i> in an orthotopic nude-mouse model. <i>Cell Cycle</i> , 2012, 11, 628-632.	1.3	80
80	Explicit hypoxia targeting with tumor suppression by creating an obligate anaerobic <i>Salmonella Typhimurium</i> strain. <i>Scientific Reports</i> , 2012, 2, 436.	1.6	110
81	Identification of tumor-specific <i>Salmonella Typhimurium</i> promoters and their regulatory logic. <i>Nucleic Acids Research</i> , 2012, 40, 2984-2994.	6.5	49
82	<i>Salmonella enterica</i> serovars Typhimurium and Typhi as model organisms. <i>Virulence</i> , 2012, 3, 377-388.	1.8	65
83	Systemic Delivery of <i>Salmonella typhimurium</i> Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. <i>Cancer Research</i> , 2012, 72, 6447-6456.	0.4	84
84	Genetic Circuits in <i>Salmonella typhimurium</i> . <i>ACS Synthetic Biology</i> , 2012, 1, 458-464.	1.9	37
86	<i>In Vivo</i> Gene Expression Dynamics of Tumor-Targeted Bacteria. <i>ACS Synthetic Biology</i> , 2012, 1, 465-470.	1.9	48
87	Bacterial vectors for imaging and cancer gene therapy: a review. <i>Cancer Gene Therapy</i> , 2012, 19, 731-740.	2.2	50
88	High Resolution <i>In Vivo</i> Bioluminescent Imaging for the Study of Bacterial Tumour Targeting. <i>PLoS ONE</i> , 2012, 7, e30940.	1.1	116
90	Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 165-176.	0.6	108
91	Effect of <i>Salmonella</i> treatment on an implanted tumor (CT26) in a mouse model. <i>Journal of Microbiology</i> , 2012, 50, 502-510.	1.3	13
92	Bacterial immunotherapy of gastrointestinal tumors. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 557-568.	0.8	26
93	Bacteria and tumours: causative agents or opportunistic inhabitants?. <i>Infectious Agents and Cancer</i> , 2013, 8, 11.	1.2	129
94	Engineering of Bacteria for the Visualization of Targeted Delivery of a Cytolytic Anticancer Agent. <i>Molecular Therapy</i> , 2013, 21, 1985-1995.	3.7	94
95	A therapeutic vaccine using <i>Salmonella</i> -modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 341-348.	0.4	17

#	ARTICLE	IF	CITATIONS
96	Expression of β -glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs. <i>Cancer Gene Therapy</i> , 2013, 20, 276-281.	2.2	14
97	Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection. <i>BMC Microbiology</i> , 2013, 13, 236.	1.3	9
98	Bacterial-directed enzyme prodrug therapy. <i>Journal of Controlled Release</i> , 2013, 170, 120-131.	4.8	61
99	New technologies in developing recombinant attenuated Salmonella vaccine vectors. <i>Microbial Pathogenesis</i> , 2013, 58, 17-28.	1.3	68
100	Measuring Growth and Gene Expression Dynamics of Tumor-Targeted <i>S. Typhimurium</i> Bacteria. <i>Journal of Visualized Experiments</i> , 2013, , e50540.	0.2	15
101	Tumor Growth Control with IDO-Silencing Salmonella Reply. <i>Cancer Research</i> , 2013, 73, 4592-4593.	0.4	2
102	Deletion of the Braun Lipoprotein-Encoding Gene and Altering the Function of Lipopolysaccharide Attenuate the Plague Bacterium. <i>Infection and Immunity</i> , 2013, 81, 815-828.	1.0	27
103	Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer. <i>Cancer Immunology Research</i> , 2013, 1, 123-133.	1.6	61
104	Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. <i>Blood</i> , 2013, 122, 705-714.	0.6	79
105	Anti-Tumoral Effect of the Mitochondrial Target Domain of Noxa Delivered by an Engineered Salmonella typhimurium. <i>PLoS ONE</i> , 2014, 9, e80050.	1.1	71
106	Attenuated <i>Listeria monocytogenes</i> : a powerful and versatile vector for the future of tumor immunotherapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2014, 4, 51.	1.8	112
107	Tumor-targeting <i>Salmonella typhimurium</i> A1-R decoys quiescent cancer cells to cycle as visualized by Fucci imaging and become sensitive to chemotherapy. <i>Cell Cycle</i> , 2014, 13, 3958-3963.	1.3	96
108	Salmonella as an Innovative Therapeutic Antitumor Agent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 14546-14554.	1.8	46
109	Imaging for Infection: From Visualization of Inflammation to Visualization of Microbes. <i>Surgical Infections</i> , 2014, 15, 700-707.	0.7	31
110	Phenotypic Evolution of Therapeutic <i>Salmonella enterica</i> Serovar Typhimurium after Invasion of TRAMP Mouse Prostate Tumor. <i>MBio</i> , 2014, 5, e01182-14.	1.8	19
111	<i>Salmonella enterica</i> serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. <i>Immunology</i> , 2014, 143, 428-437.	2.0	53
112	<i>Salmonella</i> Typhimurium mutant strain capable of RNAi delivery. <i>Cancer Biology and Therapy</i> , 2014, 15, 1068-1076.	1.5	23
113	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014, 20, 3753-3762.	3.2	64

#	ARTICLE	IF	CITATIONS
114	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	5.8	285
115	Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy. <i>Molecular Therapy</i> , 2014, 22, 1188-1197.	3.7	37
116	Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated <i>Salmonella</i> eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice. <i>BMC Cancer</i> , 2015, 15, 620.	1.1	30
117	Persistent enhancement of bacterial motility increases tumor penetration. <i>Biotechnology and Bioengineering</i> , 2015, 112, 2397-2405.	1.7	24
118	Treating cancer with infection: a review on bacterial cancer therapy. <i>Letters in Applied Microbiology</i> , 2015, 61, 107-112.	1.0	13
119	Combined bacterial and viral treatment: a novel anticancer strategy. <i>Central-European Journal of Immunology</i> , 2015, 3, 366-372.	0.4	6
120	The engineered <i>Salmonella typhimurium</i> inhibits tumorigenesis in advanced glioma. <i>OncoTargets and Therapy</i> , 2015, 8, 2555.	1.0	6
121	Vasculature Disruption Enhances Bacterial Targeting of Autochthonous Tumors. <i>Journal of Cancer</i> , 2015, 6, 843-848.	1.2	15
122	Synthetic biology expands chemical control of microorganisms. <i>Current Opinion in Chemical Biology</i> , 2015, 28, 20-28.	2.8	27
123	Programmable probiotics for detection of cancer in urine. <i>Science Translational Medicine</i> , 2015, 7, 289ra84.	5.8	326
124	Trg-deficient <i>Salmonella</i> colonize quiescent tumor regions by exclusively penetrating or proliferating. <i>Journal of Controlled Release</i> , 2015, 199, 180-189.	4.8	27
125	Rescuing chemotaxis of the anticancer agent <i>Salmonella enterica</i> serovar Typhimurium VNP20009. <i>Journal of Biotechnology</i> , 2015, 211, 117-120.	1.9	17
126	Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 423-434.	0.6	36
127	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2015, , 135-183.		0
128	<i>Salmonella</i> -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1096-1107.	1.6	58
129	Efficiency of Conditionally Attenuated <i>Salmonella enterica</i> Serovar Typhimurium in Bacterium-Mediated Tumor Therapy. <i>MBio</i> , 2015, 6, .	1.8	68
130	Potent and tumor specific: arming bacteria with therapeutic proteins. <i>Therapeutic Delivery</i> , 2015, 6, 385-399.	1.2	40
131	Engineering Nanoparticle-Coated Bacteria as Oral DNA Vaccines for Cancer Immunotherapy. <i>Nano Letters</i> , 2015, 15, 2732-2739.	4.5	213

#	ARTICLE	IF	CITATIONS
132	Programming Controlled Adhesion of <i>E. coli</i> to Target Surfaces, Cells, and Tumors with Synthetic Adhesins. <i>ACS Synthetic Biology</i> , 2015, 4, 463-473.	1.9	133
133	<i>Salmonella</i> overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression. <i>Oncotarget</i> , 2016, 7, 374-385.	0.8	37
134	Strains, Mechanism, and Perspective: <i>Salmonella</i> -Based Cancer Therapy. <i>International Journal of Microbiology</i> , 2016, 2016, 1-10.	0.9	47
135	Bacteria in Cancer Therapy: Renaissance of an Old Concept. <i>International Journal of Microbiology</i> , 2016, 2016, 1-14.	0.9	117
136	Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential. <i>Oncotarget</i> , 2016, 7, 22605-22622.	0.8	35
137	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e51.	1.0	99
138	Targeted Cancer Therapy Using Engineered <i>Salmonella typhimurium</i> . <i>Chonnam Medical Journal</i> , 2016, 52, 173.	0.5	59
139	Efficacy of Tumor-Targeting <i>Salmonella</i> A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0160882.	1.1	93
140	<i>Salmonella</i> Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0160926.	1.1	9
141	RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated <i>Salmonella</i> -mediated Cancer Therapy. <i>Theranostics</i> , 2016, 6, 1672-1682.	4.6	107
142	EGFR-targeted Chimeras of <i>Pseudomonas</i> ToxA released into the extracellular milieu by attenuated <i>Salmonella</i> selectively kill tumor cells. <i>Biotechnology and Bioengineering</i> , 2016, 113, 2698-2711.	1.7	16
143	Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy. <i>Scientific Reports</i> , 2016, 6, 29774.	1.6	10
144	Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated <i>Salmonella typhimurium</i> using a dual fluorescent live tracking system. <i>Cancer Biology and Therapy</i> , 2016, 17, 732-740.	1.5	22
145	A phase I clinical study to evaluate safety of orally administered, genetically engineered <i>Salmonella enterica</i> serovar <i>Typhimurium</i> for canine osteosarcoma. <i>Veterinary Medicine and Science</i> , 2016, 2, 179-190.	0.6	42
146	Biomimetic <i>Salmonella</i> : A Next-Generation Therapeutic Vector?. <i>Trends in Microbiology</i> , 2016, 24, 850-852.	3.5	16
147	A <i>Salmonella</i> nanoparticle mimic overcomes multidrug resistance in tumours. <i>Nature Communications</i> , 2016, 7, 12225.	5.8	62
148	Antimelanoma effect of <i>Salmonella</i> Typhimurium integration host factor mutant in murine model. <i>Future Oncology</i> , 2016, 12, 2367-2378.	1.1	2
149	Biobots. <i>Microbes and Infection</i> , 2016, 18, 373-377.	1.0	3

#	ARTICLE	IF	CITATIONS
150	Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 330-339.	3.2	56
151	Bacterial Carriers for Glioblastoma Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 1-17.	2.0	26
152	Carcinogenesis and therapeutics: the microbiota perspective. <i>Nature Microbiology</i> , 2017, 2, 17008.	5.9	108
153	Two-step enhanced cancer immunotherapy with engineered <i>Salmonella typhimurium</i> secreting heterologous flagellin. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	373
154	Optimizing the restored chemotactic behavior of anticancer agent <i>Salmonella enterica</i> serovar Typhimurium VNP20009. <i>Journal of Biotechnology</i> , 2017, 251, 76-83.	1.9	20
155	Utilizing <i>Salmonella</i> to treat solid malignancies. <i>Journal of Surgical Oncology</i> , 2017, 116, 75-82.	0.8	7
156	Intracellular delivery of biologic therapeutics by bacterial secretion systems. <i>Expert Reviews in Molecular Medicine</i> , 2017, 19, e6.	1.6	22
157	Anticancer effects of the microbiome and its products. <i>Nature Reviews Microbiology</i> , 2017, 15, 465-478.	13.6	399
158	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	1.3	37
159	Advances in bacterial cancer therapies using synthetic biology. <i>Current Opinion in Systems Biology</i> , 2017, 5, 1-8.	1.3	68
160	The Boosting Potential of Bacteria in Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2017, 23, 580-582.	3.5	10
161	Can a nanoparticle that mimics <i>Salmonella</i> effectively combat tumor chemotherapy resistance?. <i>Nanomedicine</i> , 2017, 12, 705-710.	1.7	2
162	Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. <i>Microbial Biotechnology</i> , 2017, 10, 1074-1078.	2.0	33
163	Designer bacteria as intratumoural enzyme biofactories. <i>Advanced Drug Delivery Reviews</i> , 2017, 118, 8-23.	6.6	18
164	Inflammation and Cancer. , 2017, , 17-24.		0
165	Autonomous bacterial nanoswimmers target cancer. <i>Journal of Controlled Release</i> , 2017, 257, 68-75.	4.8	39
166	Application of genetically engineered <i>Salmonella typhimurium</i> for interferon-gamma-induced therapy against melanoma. <i>European Journal of Cancer</i> , 2017, 70, 48-61.	1.3	74
167	Modulation of <i>Salmonella</i> Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism. <i>Theranostics</i> , 2017, 7, 2250-2260.	4.6	56

#	ARTICLE	IF	CITATIONS
168	Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model. PLoS ONE, 2017, 12, e0188960.	1.1	16
169	The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43. International Journal of Medical Sciences, 2017, 14, 1181-1188.	1.1	24
170	Anti-tumor activity of an immunotoxin (TGF β -PE38) delivered by attenuated <i>Salmonella typhimurium</i> . Oncotarget, 2017, 8, 37550-37560.	0.8	53
171	The concept of immune surveillance against tumors: The first theories. Oncotarget, 2017, 8, 7175-7180.	0.8	221
172	Therapeutic benefit of <i>Salmonella</i> attributed to LPS and TNF β is exhaustible and dictated by tumor susceptibility. Oncotarget, 2017, 8, 36492-36508.	0.8	32
173	Bacterial type III secretion system as a protein delivery tool for a broad range of biomedical applications. Biotechnology Advances, 2018, 36, 482-493.	6.0	40
174	Engineering bacteria for diagnostic and therapeutic applications. Nature Reviews Microbiology, 2018, 16, 214-225.	13.6	267
175	Conditional constitutive expression system of a drug protein in vivo by positive feedback loop using an inducer-independent artificial transcription factor. Biochemical and Biophysical Research Communications, 2018, 495, 2390-2395.	1.0	1
176	Potential usefulness of Brevibacillus for bacterial cancer therapy: intratumoral provision of tumor necrosis factor β and anticancer effects. Cancer Gene Therapy, 2018, 25, 47-57.	2.2	3
177	The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer. , 2018, , 447-462.		2
178	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. Oncoimmunology, 2018, 7, e1424676.	2.1	35
179	Peyer's Patches as a Portal for DNA Delivery by <i>Lactococcus lactis</i> in Vivo. Biological and Pharmaceutical Bulletin, 2018, 41, 190-197.	0.6	5
180	Attenuated <i>Salmonella</i> VNP20009 mutant (Δ htrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency. Letters in Applied Microbiology, 2018, 67, 97-103.	1.0	10
181	Engineered <i>Salmonella enterica</i> serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. Oncoimmunology, 2018, 7, e1382791.	2.1	46
182	Comparison of the common bacteria in human and mouse tumours using high-throughput sequencing. Molecular Medicine Reports, 2018, 17, 6717-6722.	1.1	3
183	<i>Salmonella</i> and Biotechnology. , 0, , .		0
184	Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 2018, 18, 727-743.	12.8	439
185	Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated <i>Salmonella enterica</i> . Journal of Immunology Research, 2018, 2018, 1-15.	0.9	30

#	ARTICLE	IF	CITATIONS
186	Technetium-99m-based simple and convenient radiolabeling of Escherichia coli for in vivo tracking of microorganisms. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 997-1003.	0.7	4
187	Infection by <i>Salmonella enterica</i> ; Promotes or Demotes Tumor Development. , 0, , .		1
188	Computational Models for Trapping Ebola Virus Using Engineered Bacteria. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 2017-2027.	1.9	8
189	Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano, 2018, 12, 5995-6005.	7.3	253
190	Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. Cancer Gene Therapy, 2018, 25, 167-183.	2.2	33
191	Construction of Bacteria-Based Cargo Carriers for Targeted Cancer Therapy. Methods in Molecular Biology, 2018, 1831, 25-35.	0.4	4
192	Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions. Frontiers in Microbiology, 2018, 9, 16.	1.5	98
193	Potentiating bacterial cancer therapy using hydroxychloroquine liposomes. Journal of Controlled Release, 2018, 280, 39-50.	4.8	22
194	White paper on microbial anti-cancer therapy and prevention. , 2018, 6, 78.		108
195	Camouflaging bacteria by wrapping with cell membranes. Nature Communications, 2019, 10, 3452.	5.8	149
196	Bacterial Targeting of Tumors. , 2019, , .		0
197	Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis. Journal of Cancer, 2019, 10, 4442-4454.	1.2	21
198	<i>Salmonella</i> -Mediated Cancer Therapy: An Innovative Therapeutic Strategy. Journal of Cancer, 2019, 10, 4765-4776.	1.2	45
199	Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models. Cells, 2019, 8, 599.	1.8	18
200	Application of Bacterial Whole-Cell Biosensors in Health. , 2019, , 1-17.		1
201	Oncolytic bacteria: past, present and future. FEMS Microbiology Letters, 2019, 366, .	0.7	15
202	Bacteria in Cancer Therapeutics: A Framework for Effective Therapeutic Bacterial Screening and Identification. Journal of Cancer, 2019, 10, 1781-1793.	1.2	15
203	Vaccination against <i>Clostridium difficile</i> by Use of an Attenuated <i>Salmonella enterica</i> Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge. Infection and Immunity, 2019, 87, .	1.0	6

#	ARTICLE	IF	CITATIONS
204	Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy. <i>Biomedicines</i> , 2019, 7, 36.	1.4	26
205	Rapid screening of engineered microbial therapies in a 3D multicellular model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9002-9007.	3.3	30
206	Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. <i>Cancer Medicine</i> , 2019, 8, 3167-3181.	1.3	191
207	Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. <i>Nature Communications</i> , 2019, 10, 1580.	5.8	85
208	Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy. <i>Cancer Letters</i> , 2019, 448, 168-181.	3.2	80
209	The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella. , 2019, 7, 44.		16
210	Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 258-266.	0.9	18
211	Canine Cancer: Strategies in Experimental Therapeutics. <i>Frontiers in Oncology</i> , 2019, 9, 1257.	1.3	26
212	Cancer Immunotherapy. , 2019, , 231-250.		0
213	Salmonella Typhimurium as an Anticancer Therapy: Recent Advances and Perspectives. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 225-239.	1.8	17
214	Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007490.	1.3	15
215	Bacteria-cancer interactions: bacteria-based cancer therapy. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	3.2	233
216	Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 929-939.	1.7	22
217	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019, 11, 38.	1.7	378
218	Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) Enhances Intratumoral Transport of Nanomedicine. <i>Advanced Science</i> , 2019, 6, 1801309.	5.6	104
219	Detection of tumors with fluoromarker-releasing bacteria. <i>International Journal of Cancer</i> , 2020, 146, 137-149.	2.3	12
220	Nontyphoidal Salmonella : a potential anticancer agent. <i>Journal of Applied Microbiology</i> , 2020, 128, 2-14.	1.4	11
221	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42

#	ARTICLE	IF	CITATIONS
222	The First Clinical Use of a Recombinant <i>Lactococcus lactis</i> Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and Immunogenicity Trial in Healthy Women Volunteers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 717-727.	1.9	24
223	Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. <i>Nano Letters</i> , 2020, 20, 11-21.	4.5	175
224	Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 9-24.	0.8	7
225	Bioengineered <i>Escherichia coli</i> Nissle 1917 for tumour targeting therapy. <i>Microbial Biotechnology</i> , 2020, 13, 629-636.	2.0	67
226	Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression. <i>Cancers</i> , 2020, 12, 57.	1.7	22
227	Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications. <i>Life Sciences</i> , 2020, 261, 118296.	2.0	40
228	Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7575.	1.8	44
229	Entirely Synthetic Bacterial Nanomimics for Highly-Effective Tumor Suppression and Immune Elicitation. <i>Nano Today</i> , 2020, 35, 100950.	6.2	9
230	Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics. <i>Biochimie</i> , 2020, 177, 164-189.	1.3	38
231	Microbes as Biosensors. <i>Annual Review of Microbiology</i> , 2020, 74, 337-359.	2.9	35
232	Bacteria and bacterial derivatives as drug carriers for cancer therapy. <i>Journal of Controlled Release</i> , 2020, 326, 396-407.	4.8	85
233	Engineering Living Bacteria for Cancer Therapy. <i>ACS Applied Bio Materials</i> , 2020, 3, 8136-8145.	2.3	18
234	Attenuated <i>Salmonella enterica</i> Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice. <i>Vaccines</i> , 2020, 8, 646.	2.1	2
235	Biosorption-based ⁶⁴ Cu-labeling of bacteria for pharmacokinetic positron-emission tomography. <i>International Journal of Pharmaceutics</i> , 2020, 590, 119950.	2.6	2
236	Engineering the gut microbiota to treat chronic diseases. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 7657-7671.	1.7	19
237	Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in <i>Pten</i> -deleted Mouse Models of Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 5036-5047.	3.2	6
238	Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer. <i>Science Advances</i> , 2020, 6, eaba3546.	4.7	144
239	Bacteria-Derived Nanoparticles: Multifunctional Containers for Diagnostic and Therapeutic Applications. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000893.	3.9	17

#	ARTICLE	IF	CITATIONS
240	A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated <i>Salmonella typhimurium</i> Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers. <i>Journal of Immunotherapy</i> , 2020, 43, 217-221.	1.2	27
241	Inhibition of acute leukemia with attenuated <i>Salmonella typhimurium</i> strain VNP20009. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110425.	2.5	10
242	Bacteria as a double-action sword in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188388.	3.3	38
243	Engineering probiotics as living diagnostics and therapeutics for improving human health. <i>Microbial Cell Factories</i> , 2020, 19, 56.	1.9	71
244	Bacteria and cancer: Different sides of the same coin. <i>Life Sciences</i> , 2020, 246, 117398.	2.0	38
245	Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119177.	2.6	48
246	Data-driven statistical modeling of the emergent behavior of biohybrid microrobots. <i>APL Bioengineering</i> , 2020, 4, 016104.	3.3	5
247	Hyaluronidase-Expressing <i>Salmonella</i> Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 706-716.	1.9	26
248	Imaging of tumor colonization by <i>Escherichia coli</i> using ¹⁸ F-FDS PET. <i>Theranostics</i> , 2020, 10, 4958-4966.	4.6	40
249	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2021, 70, 11-23.	4.3	26
250	Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1191-1206.	2.4	27
251	New technologies in developing recombinant-attenuated bacteria for cancer therapy. <i>Biotechnology and Bioengineering</i> , 2021, 118, 513-530.	1.7	17
252	Virulence-attenuated <i>Salmonella</i> engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer. <i>Journal of Drug Targeting</i> , 2021, 29, 430-438.	2.1	5
253	Antitumor effects and mechanisms of CpG ODN combined with attenuated <i>Salmonella</i> -delivered siRNAs against PD-1. <i>International Immunopharmacology</i> , 2021, 90, 107052.	1.7	9
254	Tweak to Treat: Reprogramming Bacteria for Cancer Treatment. <i>Trends in Cancer</i> , 2021, 7, 447-464.	3.8	71
255	“Trojan Horse”- <i>Salmonella</i> Enabling Tumor Homing of Silver Nanoparticles via Neutrophil Infiltration for Synergistic Tumor Therapy and Enhanced Biosafety. <i>Nano Letters</i> , 2021, 21, 414-423.	4.5	50
256	Ampullary Adenocarcinoma: a Mini-Review and a Case Report of a Clinically Stable Disease Patient Treated with Herbal Supplements. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 750-758.	0.6	1
257	<i>Salmonella enterica</i> Typhimurium engineered for nontoxic systemic colonization of autochthonous tumors. <i>Journal of Drug Targeting</i> , 2021, 29, 294-299.	2.1	5

#	ARTICLE	IF	CITATIONS
258	Single-celled bacteria as tool for cancer therapy. , 2021, , 103-126.		1
259	Magnetospirillum magneticum as a Living Iron Chelator Induces TfR1 Upregulation and Decreases Cell Viability in Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 498.	1.8	4
260	Synthetic Biology and Bacteria-Based. Methods in Molecular Biology, 2021, 2323, 267-280.	0.4	1
261	Microbes in Oncology: Controllable Strategies for Bacteria Therapy. BIO Integration, 2021, 1, .	0.9	4
262	Recent Progress in the Molecular Imaging of Tumor-Treating Bacteria. Nuclear Medicine and Molecular Imaging, 2021, 55, 7-14.	0.6	6
263	Bacteria-Based Cancer Immunotherapy. Advanced Science, 2021, 8, 2003572.	5.6	115
264	Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. Frontiers in Immunology, 2021, 12, 615930.	2.2	12
265	Acquired Fanconi Syndrome in a Patient with Nontyphoidal & Salmonella Bacteremia. Internal Medicine, 2021, 60, 761-764.	0.3	1
266	Phenotypic characterization of auxotrophic mutant of nontyphoidal Salmonella and determination of its cytotoxicity, tumor inhibiting cytokine gene expression in cell line models. Archives of Microbiology, 2021, 203, 2925-2939.	1.0	0
267	Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches. Frontiers in Oncology, 2021, 11, 624759.	1.3	28
268	The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. Future Microbiology, 2021, 16, 341-368.	1.0	5
269	Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. Acta Biomaterialia, 2021, 124, 72-87.	4.1	29
270	IFN- γ -dependent NK cell activation is essential to metastasis suppression by engineered Salmonella. Nature Communications, 2021, 12, 2537.	5.8	36
271	A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome, 2021, 9, 122.	4.9	81
272	Salmonella flagella confer anti-tumor immunological effect via activating Flagellin/TLR5 signalling within tumor microenvironment. Acta Pharmaceutica Sinica B, 2021, 11, 3165-3177.	5.7	27
273	Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 667897.	2.2	4
274	Integration of Salmonella into Combination Cancer Therapy. Cancers, 2021, 13, 3228.	1.7	15
275	The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer. Cancers, 2021, 13, 3004.	1.7	3

#	ARTICLE	IF	CITATIONS
276	In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium. <i>Journal of Personalized Medicine</i> , 2021, 11, 566.	1.1	8
277	Multidimensional role of bacteria in cancer: Mechanisms insight, diagnostic, preventive and therapeutic potential. <i>Seminars in Cancer Biology</i> , 2022, 86, 1026-1044.	4.3	3
278	Theranostic cells: emerging clinical applications of synthetic biology. <i>Nature Reviews Genetics</i> , 2021, 22, 730-746.	7.7	49
279	Engineering a probiotic strain of <i>Escherichia coli</i> to induce the regression of colorectal cancer through production of 5-aminolevulinic acid. <i>Microbial Biotechnology</i> , 2021, 14, 2130-2139.	2.0	14
280	Recent advancements in the exploitation of the gut microbiome in the diagnosis and treatment of colorectal cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	5
281	Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-Cancer Salmonella. <i>Frontiers in Immunology</i> , 2021, 12, 712936.	2.2	6
282	Precision strategies for cancer treatment by modifying the tumor-related bacteria. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 6183-6197.	1.7	9
283	<i>Escherichia coli</i> Nissle 1917 as a Novel Microrobot for Tumor-Targeted Imaging and Therapy. <i>Pharmaceutics</i> , 2021, 13, 1226.	2.0	19
285	Synergistic effects of arsenic trioxide combined with <i>Salmonella typhimurium</i> in treating the advanced hepatocellular carcinoma in rat models. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1732-1742.	0.6	3
286	Microbiota and Colorectal Cancer: From Gut to Bedside. <i>Frontiers in Pharmacology</i> , 2021, 12, 760280.	1.6	22
287	Therapeutic activity of a <i>Salmonella</i> -vectored <i>Schistosoma mansoni</i> vaccine in a mouse model of chronic infection. <i>Vaccine</i> , 2021, 39, 5580-5588.	1.7	6
288	Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration. <i>Vaccine</i> , 2021, 39, 5589-5599.	1.7	13
289	Both <i>Chlamydia</i> and <i>Salmonella</i> Suppress the Tumor Metastasis and Relapse via Tandem Amplifying Reactive Oxygen Species-Immunity Responses. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100950.	3.9	16
290	Bacteria-based immune therapies for cancer treatment. <i>Seminars in Cancer Biology</i> , 2022, 86, 1163-1178.	4.3	10
291	Application of Bacterial Whole-Cell Biosensors in Health. , 2022, , 945-961.		4
292	Microbiome Based Diseases Diagnostics. , 2022, , 390-401.		1
293	Engineered microbes for cancer immunotherapy. , 2022, , 33-62.		0
294	Bacteria-mediated cancer therapies: opportunities and challenges. <i>Biomaterials Science</i> , 2021, 9, 5732-5744.	2.6	22

#	ARTICLE	IF	CITATIONS
295	The Microbiome and Its Implications in Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 206.	1.7	15
296	Theranostic Approaches Using Live Bacteria. , 2021, , 983-1004.		1
297	Engineering bacteria for cancer therapy. <i>Emerging Topics in Life Sciences</i> , 2019, 3, 623-629.	1.1	11
299	Inflammation drives thrombosis after <i>Salmonella</i> infection via CLEC-2 on platelets. <i>Journal of Clinical Investigation</i> , 2015, 125, 4429-4446.	3.9	135
300	Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells. <i>AMB Express</i> , 2020, 10, 59.	1.4	8
301	Tumor Invasion of <i>Salmonella enterica</i> Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF- α . <i>PLoS ONE</i> , 2009, 4, e6692.	1.1	174
302	Live Attenuated <i>S. Typhimurium</i> Vaccine with Improved Safety in Immuno-Compromised Mice. <i>PLoS ONE</i> , 2012, 7, e45433.	1.1	25
303	Composing a Tumor Specific Bacterial Promoter. <i>PLoS ONE</i> , 2016, 11, e0155338.	1.1	9
304	Targeting tumors with salmonella Typhimurium- potential for therapy. <i>Oncotarget</i> , 2010, 1, 721-8.	0.8	29
305	The genes <i>slyA</i> , <i>STM3120</i> and <i>htrA</i> are required for the anticancer ability of VNP20009. <i>Oncotarget</i> , 2016, 7, 81187-81196.	0.8	8
306	32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. <i>Oncotarget</i> , 2017, 8, 20729-20740.	0.8	38
307	Effect of <i>Salmonella enterica</i> serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression. <i>Oncotarget</i> , 2017, 8, 33601-33613.	0.8	21
308	Toxicology and efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , 2017, 8, 54616-54628.	0.8	16
309	Local application of bacteria improves safety of <i>Salmonella</i> -mediated tumor therapy and retains advantages of systemic infection. <i>Oncotarget</i> , 2017, 8, 49988-50001.	0.8	27
310	Targeting Tumors with <i>Salmonella Typhimurium</i> - Potential for Therapy. <i>Oncotarget</i> , 2010, 1, 721-728.	0.8	47
311	Tumor-targeting <i>Salmonella typhimurium</i> A1-R prevents experimental human breast cancer bone metastasis in nude mice. <i>Oncotarget</i> , 2014, 5, 7119-7125.	0.8	34
312	Cell mass-dependent expression of an anticancer protein drug by tumor-targeted <i>Salmonella</i> . <i>Oncotarget</i> , 2018, 9, 8548-8559.	0.8	13
313	Tumor-targeting <i>Salmonella typhimurium</i> A1-R arrests growth of breast-cancer brain metastasis. <i>Oncotarget</i> , 2015, 6, 2615-2622.	0.8	59

#	ARTICLE	IF	CITATIONS
314	Comparison of the selective targeting efficacy of <i>Salmonella typhimurium</i> A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. <i>Oncotarget</i> , 2015, 6, 14625-14631.	0.8	33
315	Intraperitoneal administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice. <i>Oncotarget</i> , 2015, 6, 11369-11377.	0.8	55
316	Therapeutic efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models. <i>Oncotarget</i> , 2015, 6, 31368-31377.	0.8	14
317	Adjuvant treatment with tumor-targeting <i>Salmonella typhimurium</i> A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model. <i>Oncotarget</i> , 2015, 6, 41856-41862.	0.8	13
318	Tumor-targeting <i>Salmonella typhimurium</i> A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 12783-12790.	0.8	109
319	Blockage of autophagy pathway enhances <i>Salmonella</i> tumor-targeting. <i>Oncotarget</i> , 2016, 7, 22873-22882.	0.8	24
320	High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , 2016, 7, 33046-33054.	0.8	93
321	Solid tumors provide niche-specific conditions that lead to preferential growth of <i>Salmonella</i> . <i>Oncotarget</i> , 2016, 7, 35169-35180.	0.8	35
322	AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success. <i>Current Gene Therapy</i> , 2010, 10, 319-340.	0.9	85
323	Preclinical Evaluation of LVR01 Attenuated <i>Salmonella</i> as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1435-1443.e2.	0.3	2
324	Attenuated <i>Salmonella</i> carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy. <i>Scientific Reports</i> , 2021, 11, 20083.	1.6	3
326	Microwave ablation combined with attenuated <i>Salmonella typhimurium</i> for treating hepatocellular carcinoma in a rat model. <i>Oncotarget</i> , 2017, 8, 47655-47664.	0.8	0
328	USE OF BACTERIA IN CANCER THERAPY (REVIEW). , 2019, 18, 34-42.	0.3	0
329	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2020, , 159-212.		0
330	Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape. <i>JCI Insight</i> , 2021, 6, .	2.3	4
331	Avengers against cancer: A new era of nano-biomaterial-based therapeutics. <i>Materials Today</i> , 2021, 51, 317-349.	8.3	24
332	Highlights of Immunomodulation in <i>Salmonella</i> -Based Cancer Therapy. <i>Biomedicines</i> , 2021, 9, 1566.	1.4	4
333	Bacteria in cancer therapy: Strategies to improvement and future directions. , 2020, , 191-202.		0

#	ARTICLE	IF	CITATIONS
334	Recombinant Viral and Bacterial Vaccines. , 2007, , 217-250.		0
335	Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model. <i>Oncotarget</i> , 2020, 11, 3943-3958.	0.8	0
336	Antitumor effects in mice of the intravenous injection of attenuated <i>Salmonella typhimurium</i> . <i>Journal of Immunotherapy</i> , 2002, 25, 218-25.	1.2	23
340	Studying the effects of several heat-inactivated bacteria on colon and breast cancer cells. <i>Molecular Biology Research Communications</i> , 2019, 8, 91-98.	0.2	4
341	Co-Expression of a Chimeric Protease Inhibitor Secreted by a Tumor-Targeted Protects Therapeutic Proteins from Proteolytic Degradation. <i>Journal of Microbiology and Biotechnology</i> , 2018, 28, 2079-2094.	0.9	0
342	Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. <i>Journal of Controlled Release</i> , 2022, 341, 227-246.	4.8	65
343	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112443.	2.5	12
344	Robust and Repeatable Biofabrication of Bacteria-Mediated Drug Delivery Systems: Effect of Conjugation Chemistry, Assembly Process Parameters, and Nanoparticle Size. <i>Advanced Intelligent Systems</i> , 2022, 4, 2100135.	3.3	6
345	<i>Fusobacterium nucleatum</i> enhances the efficacy of PD-L1 blockade in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 398.	7.1	84
346	Aptamer-assisted tumor localization of bacteria for enhanced biotherapy. <i>Nature Communications</i> , 2021, 12, 6584.	5.8	85
347	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. <i>Nanomaterials</i> , 2021, 11, 3018.	1.9	8
348	Bacteria and bacterial derivatives as delivery carriers for immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114085.	6.6	32
349	Dual Functionalized <i>Lactococcus lactis</i> Shows Tumor Antigen Targeting and Cytokine Binding in Vitro. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 822823.	2.0	3
350	Synthetic gene circuits for higher-order information processing. , 2022, , 373-395.		1
351	Bacterial couriers as cancer vaccines. <i>Nature Biomedical Engineering</i> , 2022, 6, 3-5.	11.6	3
352	Engineered Bacteria for Enhanced Radiotherapy against Breast Carcinoma. <i>ACS Nano</i> , 2022, 16, 801-812.	7.3	41
353	Host Microbiomes in Tumor Precision Medicine: How far are we?. <i>Current Medicinal Chemistry</i> , 2022, 29, 3202-3230.	1.2	7
354	Chemically Enhanced Live Probiotic for In Vivo Tumor Targeting and Inhibition. <i>ACS Applied Polymer Materials</i> , 2022, 4, 1368-1376.	2.0	4

#	ARTICLE	IF	CITATIONS
355	Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment. , 2022, 10, e003760.		15
356	L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2393-2410.	0.9	2
357	Bugs as drugs: neglected but a promising future therapeutic strategy in cancer. <i>Future Oncology</i> , 2022, 18, 1609-1626.	1.1	4
358	The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development. <i>BMC Microbiology</i> , 2022, 22, 53.	1.3	25
359	Optimized Attenuated Salmonella Typhimurium Suppressed Tumor Growth and Improved Survival in Mice. <i>Frontiers in Microbiology</i> , 2021, 12, 774490.	1.5	10
361	Background-suppressed tumor-targeted photoacoustic imaging using bacterial carriers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
362	A programmable encapsulation system improves delivery of therapeutic bacteria in mice. <i>Nature Biotechnology</i> , 2022, 40, 1259-1269.	9.4	89
363	Bacterial cancer therapy: A turning point for new paradigms. <i>Drug Discovery Today</i> , 2022, 27, 2043-2050.	3.2	12
364	Reprogramming Synthetic Cells for Targeted Cancer Therapy. <i>ACS Synthetic Biology</i> , 2022, 11, 1349-1360.	1.9	12
365	Advancement and Applications of Platelet-Inspired Nanoparticles: A Paradigm for Cancer Targeting. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	1
366	Bacteria-Based Synergistic Therapy in the Backdrop of Synthetic Biology. <i>Frontiers in Oncology</i> , 2022, 12, 845346.	1.3	3
367	Recent Update on Bacteria as a Delivery Carrier in Cancer Therapy: From Evil to Allies. <i>Pharmaceutical Research</i> , 2022, 39, 1115-1134.	1.7	9
368	Anaerobic bacteria mediated "smart missile" targeting tumor hypoxic area enhances the therapeutic outcome of lung cancer. <i>Chemical Engineering Journal</i> , 2022, 438, 135566.	6.6	13
369	Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy. <i>Vaccines</i> , 2021, 9, 1497.	2.1	38
370	Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8069-8086.	3.3	14
371	Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. <i>Global Challenges</i> , 2022, 6, 2100051.	1.8	0
372	Engineering Bacteria and Bionic Bacterial Derivatives with Nanoparticles for Cancer Therapy. <i>Small</i> , 2022, 18, e2104643.	5.2	32
373	Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8159-8184.	3.3	14

#	ARTICLE	IF	CITATIONS
374	Bacterially Synthesized Tellurium Nanorods for Elimination of Advanced Malignant Tumor by Photothermal Immunotherapy. <i>Small</i> , 2022, 18, e2105716.	5.2	19
375	Pattern of F-18 FDG Uptake in Colon Cancer after Bacterial Cancer Therapy Using Engineered <i>Salmonella Typhimurium</i> : A Preliminary <i>In Vivo</i> Study. <i>Molecular Imaging</i> , 2022, 2022, 9222331.	0.7	2
376	Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114295.	6.6	21
377	<i>S. enterica</i> -based antigen delivery systems. , 0, , 337-370.		0
378	Microbiota in health and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 135.	7.1	494
380	Tailoring bismuth-based nanoparticles for enhanced radiosensitivity in cancer therapy. <i>Nanoscale</i> , 2022, 14, 8245-8254.	2.8	10
381	A computational framework for investigating bacteria transport in microvasculature. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2022, , 1-12.	0.9	1
382	Macrophage-mediated tumor-targeted delivery of engineered <i>Salmonella typhimurium</i> VNP20009 in anti-PD1 therapy against melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3952-3971.	5.7	11
383	Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114340.	6.6	16
384	Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. <i>Biomaterials</i> , 2022, 286, 121582.	5.7	24
385	Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy. <i>Nano Letters</i> , 2022, 22, 5055-5064.	4.5	30
386	Bacteria-assisted delivery and oxygen production of nano-enzyme for potent radioimmunotherapy of cancer. <i>Nano Research</i> , 2022, 15, 7355-7365.	5.8	9
387	Intratumor microbiome in cancer progression: current developments, challenges and future trends. <i>Biomarker Research</i> , 2022, 10, .	2.8	25
388	Bacterially mediated drug delivery and therapeutics: Strategies and advancements. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114363.	6.6	21
389	Targeting primary and metastatic tumor growth in an aggressive breast cancer by engineered tryptophan auxotrophic <i>Salmonella Typhimurium</i> . <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 350-363.	2.0	9
390	Engineered microbial systems for advanced drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114364.	6.6	18
391	Current Status and Future Directions of Bacteria-Based Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
392	Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. <i>Npj Vaccines</i> , 2022, 7, .	2.9	5

#	ARTICLE	IF	CITATIONS
393	Trojan Nanobacteria System for Photothermal Programmable Destruction of Deep Tumor Tissues. <i>Angewandte Chemie</i> , 0, , .	1.6	1
394	Trojan Nanobacteria System for Photothermal Programmable Destruction of Deep Tumor Tissues. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	23
395	Intratumoral injection of schwannoma with attenuated <i>Salmonella typhimurium</i> induces antitumor immunity and controls tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
396	Comparison of Anticancer Activities and Biosafety Between <i>Salmonella enterica</i> Serovar Typhimurium Δ ppGpp and VNP20009 in a Murine Cancer Model. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
397	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114447.	6.6	24
398	Multimodal oncolytic bacteria by coating with tumor cell derived nanoshells. <i>Nano Today</i> , 2022, 45, 101537.	6.2	20
399	Advances of bacteria-based delivery systems for modulating tumor microenvironment. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114444.	6.6	18
400	A SARS-CoV-2 oral vaccine development strategy based on the attenuated <i>Salmonella</i> type III secretion system. <i>Journal of Applied Microbiology</i> , 2022, 133, 2484-2500.	1.4	3
401	<i>Salmonella</i> -induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. <i>Current Research in Immunology</i> , 2022, 3, 159-166.	1.2	0
402	A rapid screening platform to coculture bacteria within tumor spheroids. <i>Nature Protocols</i> , 2022, 17, 2216-2239.	5.5	7
403	Flagellated bacterial porter for in situ tumor vaccine. <i>Microbial Cell</i> , 2022, 9, 158-161.	1.4	1
404	Impact of tumoral structure and bacterial species on growth and biodistribution of live bacterial therapeutics in xenografted tumours. <i>Journal of Drug Targeting</i> , 2023, 31, 194-205.	2.1	2
405	Attenuated <i>Salmonella Typhimurium</i> with truncated LPS and outer membrane-displayed RGD peptide for cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113682.	2.5	3
406	Human microbiota: role in cancer progression and therapy. , 2022, , 145-175.		1
407	In-Situ Synthesis of Melanin in Tumor with Engineered Probiotics for Hyperbaric Oxygen-Synergized Photothermal Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
408	Utilizing Bacteria-Derived Components for Cancer Immunotherapy. <i>BIO Integration</i> , 2022, 3, .	0.9	1
409	Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?. <i>Microorganisms</i> , 2022, 10, 1733.	1.6	4
410	Recombinant Attenuated <i>Salmonella enterica</i> as a Delivery System of Heterologous Molecules in Cancer Therapy. <i>Cancers</i> , 2022, 14, 4224.	1.7	10

#	ARTICLE	IF	CITATIONS
411	Antitumor effect of <i>Escherichia coli</i> -derived outer membrane vesicles on neuroblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	3
412	Bacteria-mediated tumor-targeted delivery of tumstatin (54-132) significantly suppresses tumor growth in mouse model by inhibiting angiogenesis and promoting apoptosis. <i>Frontiers of Medicine</i> , 2022, 16, 873-882.	1.5	1
413	Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth. <i>Cancers</i> , 2022, 14, 4614.	1.7	3
414	Recent advances in bacterial therapeutics based on sense and response. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1014-1027.	5.7	4
416	Bacteriolytic therapy with <i>Clostridium ghonii</i> for experimental solid tumors. <i>Biochemical and Biophysical Research Communications</i> , 2022, 634, 114-121.	1.0	2
417	Bacteria-mediated cancer therapy: A versatile bio-sapper with translational potential. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
418	In-situ synthesis of melanin in tumor with engineered probiotics for hyperbaric oxygen-synergized photothermal immunotherapy. <i>Nano Today</i> , 2022, 47, 101632.	6.2	10
419	Designer Microbes: Oncotherapy Approach. , 2022, , 231-247.		0
420	Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence. , 2022, , 3-40.		0
421	Magnetic torque-driven living microrobots for increased tumor infiltration. <i>Science Robotics</i> , 2022, 7, .	9.9	52
422	Recent advances in bacteria-mediated cancer therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7
423	Salmonella as a Promising Curative Tool against Cancer. <i>Pharmaceutics</i> , 2022, 14, 2100.	2.0	12
424	Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. <i>Nature Communications</i> , 2022, 13, .	5.8	44
425	Recent Advances in Bacteria-Based Cancer Treatment. <i>Cancers</i> , 2022, 14, 4945.	1.7	9
426	Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding <i>S. typhimurium</i> . <i>Journal of Controlled Release</i> , 2022, 351, 860-871.	4.8	6
427	Recent Progress and Trends in X-ray-Induced Photodynamic Therapy with Low Radiation Doses. <i>ACS Nano</i> , 2022, 16, 19691-19721.	7.3	27
428	Prospect of bacteria for tumor diagnosis and treatment. <i>Life Sciences</i> , 2023, 312, 121215.	2.0	2
429	Intratumoral bacteria are an important accomplice in tumor development and metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188846.	3.3	8

#	ARTICLE	IF	CITATIONS
430	Engineering bacteria as interactive cancer therapies. <i>Science</i> , 2022, 378, 858-864.	6.0	74
431	Anti-Tumor Effects of Engineered VNP20009-Abvec-Ig ¹ ₂ -mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 2789.	2.0	2
432	Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
433	Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy. <i>ACS Nano</i> , 2023, 17, 843-884.	7.3	7
434	Modification of bacterial cells for in vivo remotely guided systems. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	0
435	Engineered bacteria for augmented <i>in situ</i> tumor vaccination. <i>Biomaterials Science</i> , 2023, 11, 1137-1152.	2.6	6
436	Manipulating the Gut Microbiome as a Therapeutic Strategy to Mitigate Late Effects in Childhood Cancer Survivors. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211497.	0.8	1
437	Recent Advances in Contrast-Enhanced Photoacoustic Imaging: Overcoming the Physical and Practical Challenges. <i>Chemical Reviews</i> , 2023, 123, 7379-7419.	23.0	39
438	Microbes used as anticancer agents and their potential application in biomedicine. , 2023, , 173-215.		0
439	Applications of Bacteria Decorated with Synthetic DNA Constructs. <i>Small</i> , 2023, 19, .	5.2	1
441	ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models. <i>Journal of Controlled Release</i> , 2023, 355, 199-210.	4.8	5
442	<i>Salmonella typhimurium</i> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
443	Programming the lifestyles of engineered bacteria for cancer therapy. <i>National Science Review</i> , 2023, 10, .	4.6	8
444	<i>Salmonella Typhimurium</i> expressing chromosomally integrated <i>Schistosoma mansoni</i> Cathepsin B protects against schistosomiasis in mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	2
445	Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context. <i>Advanced Science</i> , 2023, 10, .	5.6	5
446	<i>Blautia coccoides</i> JCM1395T Achieved Intratumoral Growth with Minimal Inflammation: Evidence for Live Bacterial Therapeutic Potential by an Optimized Sample Preparation and Colony PCR Method. <i>Pharmaceutics</i> , 2023, 15, 989.	2.0	1
447	Using bugs as drugs: Administration of bacteria-related microbes to fight cancer. <i>Advanced Drug Delivery Reviews</i> , 2023, 197, 114825.	6.6	1
448	Ectopic expression of cGAS in <i>Salmonella typhimurium</i> enhances STING-mediated IFN- ¹ ₂ response in human macrophages and dendritic cells. , 2023, 11, e005839.		1

#	ARTICLE	IF	CITATIONS
452	Microbiome therapeutics for the cancer management. , 2023, , 197-230.		0
456	Microbial applications for sustainable space exploration beyond low Earth orbit. Npj Microgravity, 2023, 9, .	1.9	7
460	Applications of synthetic biology in medical and pharmaceutical fields. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	17
473	Surface-modified bacteria: synthesis, functionalization and biomedical applications. Chemical Society Reviews, 2023, 52, 6617-6643.	18.7	5
474	Bacterial therapies at the interface of synthetic biology and nanomedicine. , 2024, 2, 120-135.		6
487	Genetically engineered bacteria: a new frontier in targeted drug delivery. Journal of Materials Chemistry B, 2023, 11, 10072-10087.	2.9	4
493	Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment. Npj Biofilms and Microbiomes, 2023, 9, .	2.9	1
499	Bacteria and Bacteria-Based Products in Cancer Therapy: Current Status and Future Advances. , 2023, , 441-470.		0
500	A Systemic Review on Fitness and Survival of Salmonella in Dynamic Environment and Conceivable Ways of Its Mitigation. Indian Journal of Microbiology, 0, , .	1.5	0